Citations

Clear

6273 citation(s) found for "To, Andrew".

Outcome Following Aminosalicylate Therapy in Children Newly Diagnosed As Having Ulcerative Colitis
Zeisler, Bella, Lerer, Trudy, Markowitz, James , Mack, David , Bousvaros, Athos, Keljo, David J., Rosh, Joel R. , Evans, Jonathan, Otley, Anthony , Kay, Marsha , Grossman, Andrew B., Saeed, Shehzad A. , Carvalho, Ryan , Oliva‐Hemker, Maria , Faubion, William A. , Sudel, Boris , Pfefferkorn, Marian, Ashai-Khan, Farhat N., LeLeiko, Neal S. , Hyams, Jeffrey S. , Griffiths, Anne Marie , Kappelman, Michael D. , Leleiko, Neal S

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | November 17, 2012 | Volume: 56 | Issue: 1 | Pages: 12-18

10.1097/mpg.0b013e31826ac41a | PMID 22847466 Get It

ABSTRACTObjectives:Despite a paucity of published supporting data, 5‐aminosalicylate (5‐ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5‐ASA.Methods:Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5‐ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy).Results:Study subjects included 213 patients newly diagnosed as having UC who received oral 5‐ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40%) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5‐ASA used.Conclusions:Forty percent of children taking 5‐ASA as primary maintenance therapy at diagnosis are in CS‐free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.
inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations
Schwind, Sebastian , Edwards, Colin G., Mrózek, Krzysztof , Maharry, Kati , Wu, Yue-Zhong, Paschka, Peter , Eisfeld, Ann‐Kathrin , Hoellerbauer, Pia , Becker, Heiko , Metzeler, Klaus H. , Curfman, John, Kohlschmidt, Jessica, Prior, Thomas W., Kolitz, Jonathan E. , Blum, William , Pettenati, Mark J., Cin, Paola Dal , Carroll, Andrew J. , Larson, Richard A. , Volinia, Stefano , Marcucci, Guido , Bloomfield, Clara D. , Nicolet, Deedra , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | November 17, 2012 | Volume: 121 | Issue: 2 | Pages: 385-391

10.1182/blood-2012-07-442772 | PMID 23160462 Get It

Abstract The inv(16)(p13q22)/t(16;16)(p13;q22) in acute myeloid leukemia results in multiple CBFB-MYH11 fusion transcripts, with type A being most frequent. The biologic and prognostic implications of different fusions are unclear. We analyzed CBFB-MYH11 fusion types in 208 inv(16)/t(16;16) patients with de novo disease, and compared clinical and cytogenetic features and the KIT mutation status between type A (n = 182; 87%) and non–type A (n = 26; 13%) patients. At diagnosis, non–type A patients had lower white blood counts (P = .007), and more often trisomies of chromosomes 8 (P = .01) and 21 (P < .001) and less often trisomy 22 (P = .02). No patient with non–type A fusion carried a KIT mutation, whereas 27% of type A patients did (P = .002). Among the latter, KIT mutations conferred adverse prognosis; clinical outcomes of non–type A and type A patients with wild-type KIT were similar. We also derived a fusion-type–associated global gene-expression profile. Gene Ontology analysis of the differentially expressed genes revealed—among others—an enrichment of up-regulated genes involved in activation of caspase activity, cell differentiation and cell cycle control in non–type A patients. We conclude that non–type A fusions associate with distinctclinical and genetic features, including lack of KIT mutations, and a unique gene-expression profile.
Effect of Age on the Clinical Presentation of Incident Symptomatic Urolithiasis in the General Population
Krambeck, Amy E. , Li, Xujian, Bergstralh, Eric J., Melton, L. Joseph, Lieske, John C. , Rule, Andrew D.

Mayo Clinic

Journal of Urology | November 16, 2012 | Volume: 189 | Issue: 1 | Pages: 158-164

10.1016/j.juro.2012.09.023 | PMID 23164393 Get It

Self-Report of Child Care Directors Regarding Return-to-Care
Hashikawa, Andrew N. , Stevens, Martha W., Juhn, Young J. , Nimmer, Mark, Copeland, Kristen A. , Simpson, Pippa , Brousseau, David C.

Mayo Clinic

Pediatrics | November 13, 2012 | Volume: 130 | Issue: 6 | Pages: 1046-1052

10.1542/peds.2012-1184 | PMID 23147967 Get It

BACKGROUND:The American Academy of Pediatrics (AAP) introduced revised return-to-care recommendations for mildly ill children in 2009 that were added to national standards in 2011. Child care directors' practices in a state without clear emphasis on return-to-care guidelines are unknown. We investigated director return-to-care practices just before the release of recently revised AAP guidelines.METHODS:A telephone survey with 5 vignettes of mild illness (cold symptoms, conjunctivitis, vomiting/diarrhea, fever, and ringworm) was administered to randomly sampled directors in metropolitan Milwaukee, Wisconsin. Directors were asked about return-to-care criteria for each illness. Questions for return-to-care criteria were open-ended; multiple responses were allowed. Answers were compared with AAP return-to-care recommendations.RESULTS:A total of 305 directors participated. Based on director responses to vignettes, the percentage of correct responses regarding return-to-child care management compared with AAP return-to-care recommendations was low: fever (0%); conjunctivitis (0%); diarrhea (1.6%); cold symptoms (12%); ringworm (21%); and vomiting (80%). Two illnesses (conjunctivitis and cold symptoms) would require the child to have an urgent medical evaluation or treatment not recommended by the AAP, as follows: Conjunctivitis—antibiotics for 24 hours (62%), physician visit (49%), any antibiotic treatment (6%), and symptom resolution (4%); and Cold Symptoms—physician visit (45.6%), antibiotics (10%), and symptom resolution (25%).CONCLUSIONS:Directors’ self-reported return-to-child care practices differed substantially before the release of revised AAP return-to-care recommendations. Active adoption of AAP return-to-child care guidelines would decrease the need for unnecessary urgent medical evaluation and treatment as well as unnecessary exclusion of a child from child care.
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants
Sharma, Manu , Aasly, Jan , Annesi, Grazia , Brice, Alexis , Bozi, Maria , Barcikowska, Maria , Crosiers, David , Clarke, Carl E , Facheris, Maurizio , Farrer, Matthew J. , Garraux, Gaëtan , Gispert, Suzana, Auburger, Georg , Vilariño‐Güell, Carles , Hicks, Andrew A. , Hattori, Nobutaka , Jeon, Beom S., Jamrozik, Zygmunt , Krygowska‐Wajs, Anna, Lesage, Suzanne , Lill, Christina M. , Lin, Juei‐Jueng , Lynch, Timothy , Lichtner, Peter , Lang, Anthony E. , Libioulle, Cécile , Murata, Miho, Mok, Vincent , Jasińska‐Myga, Barbara, Mellick, George D. , Morrison, Karen , Meitnger, Thomas, Zimprich, Alexander , Opala, Grzegorz, Pramstaller, Peter P. , Pichler, Irene , Park, Sung Sup , Quattrone, Aldo , Ross, Owen A. , Stockton, Joanne , Satake, Wataru , Silburn, Peter A., Strom, Tim M., Theuns, Jessie , Tan, Eng King, Tomiyama, Hiroyuki , Uitti, Ryan J. , Broeckhoven, Christine Van , Wirdefeldt, Karin , Xiromerisiou, Georgia , Yomono, Harumi, Yueh, Kuo-Chu, Zhao, Yi , Gasser, Thomas , Maraganore, Demetrius M. , Krüger, Rejko , Ioannidis, John P. A. , Bertram, Lars , Hadjigeorgiou, Georgios M. , Rogaeva, Ekaterina A. , Stefanis, Leonidas , Toda, Tatsushi , Wszołek, Zbigniew K. , Lang, Anthony E , Ross, Owen A , Zimprich, Alexander , Brice, Alexis

Mayo Clinic

Journal of Medical Genetics | November 2, 2012 | Volume: 49 | Issue: 11 | Pages: 721-726

10.1136/jmedgenet-2012-101155 | PMID 23125461 Get It

Background Two recent studies identified a mutation (p.Asp620Asn) in the vacuolar protein sorting 35 gene as a cause for an autosomal dominant form of Parkinson disease . Although additional missense variants were described, their pathogenic role yet remains inconclusive. Methods and results We performed the largest multi-center study to ascertain the frequency and pathogenicity of the reported vacuolar protein sorting 35 gene variants in more than 15,000 individuals worldwide. p.Asp620Asn was detected in 5 familial and 2 sporadic PD cases and not in healthy controls, p.Leu774Met in 6 cases and 1 control, p.Gly51Ser in 3 cases and 2 controls. Overall analyses did not reveal any significant increased risk for p.Leu774Met and p.Gly51Ser in our cohort. Conclusions Our study apart from identifying the p.Asp620Asn variant in familial cases also identified it in idiopathic Parkinson disease cases, and thus provides genetic evidence for a role of p.Asp620Asn in Parkinson disease in different populations worldwide.
Migraine headache is present in the aura phase
Hansen, Jakob Møller , Silberstein, Stephen D., Saper, Joel R., Aurora, Sheena K. , Goadsby, Peter J. , Charles, Andrew , Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J , Charles, Andrew

Mayo Clinic

Neurology | November 1, 2012 | Volume: 79 | Issue: 20 | Pages: 2044-2049

10.1212/wnl.0b013e3182749eed | PMID 23115208 Get It

Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography
Burghardt, Andrew J. , Kazakia, Galateia J. , Boutroy, Stéphanie , Patsch, Janina , Valentinitsch, Alexander , Liu, Danmei , Szabó, Éva , Bogado, César E., McKay, Heather , Shane, Elizabeth , Boyd, Steven K. , Bouxsein, Mary , Khosla, Sundeep , Pialat, Jean‐Baptiste , Engelke, Klaus , Zanchetta, María Belén , Chapurlat, Roland D , Majumdar, Sharmila , Khosla, Sundeep , Boyd, Steven K

Mayo Clinic

Journal of Bone and Mineral Research | October 16, 2012 | Volume: 28 | Issue: 3 | Pages: 524-536

10.1002/jbmr.1795 | PMID 23074145 Get It

Abstract High-resolution peripheral quantitative computed tomography (HR-pQCT) has recently been introduced as a clinical research tool for in vivo assessment of bone quality. The utility of this technology to address important skeletal health questions requires translation to standardized multicenter data pools. Our goal was to evaluate the feasibility of pooling data in multicenter HR-pQCT imaging trials. Reproducibility imaging experiments were performed using structure and composition-realistic phantoms constructed from cadaveric radii. Single-center precision was determined by repeat scanning over short-term (&lt;72 hours), intermediate-term (3–5 months), and long-term intervals (28 months). Multicenter precision was determined by imaging the phantoms at nine different HR-pQCT centers. Least significant change (LSC) and root mean squared coefficient of variation (RMSCV) for each interval and across centers was calculated for bone density, geometry, microstructure, and biomechanical parameters. Single-center short-term RMSCVs were &lt;1% for all parameters except cortical thickness (Ct.Th) (1.1%), spatial variability in cortical thickness (Ct.Th.SD) (2.6%), standard deviation of trabecular separation (Tb.Sp.SD) (1.8%), and porosity measures (6% to 8%). Intermediate-term RMSCVs were generally not statistically different from short-term values. Long-term variability was significantly greater for all density measures (0.7% to 2.0%; p &lt; 0.05 versus short-term) and several structure measures: cortical thickness (Ct.Th) (3.4%; p &lt; 0.01 versus short-term), cortical porosity (Ct.Po) (15.4%; p &lt; 0.01 versus short-term), and trabecular thickness (Tb.Th) (2.2%; p &lt; 0.01 versus short-term). Multicenter RMSCVs were also significantly higher than short-term values: 2% to 4% for density and micro–finite element analysis (µFE) measures (p &lt; 0.0001), 2.6% to 5.3% for morphometric measures (p &lt; 0.001), whereas Ct.Po was 16.2% (p &lt; 0.001). In the absence of subject motion, multicenter precision errors for HR-pQCT parameters were generally less than 5%. Phantom-based multicenter precision was comparable to previously reported in in vivo single-center precision errors, although this was approximately two to five times worse than ex vivo short-term precision. The data generated from this study will contribute to the future design and validation of standardized procedures that are broadly translatable to multicenter study designs. © 2013 American Society for Bone and Mineral Research.
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium
Nieters, Alexandra, Conde, Lucía , Morton, Lindsay M. , Skibola, Danica R., Novak, Anne J. , Riby, Jacques, Ansell, Stephen M. , Halperin, Eran , Agana, Luz, Wang, Alice H., Roos, Anneclaire J. De , Severson, Richard K., Spinelli, John, Butterbach, Katja, Becker, Nikolaus, Sanjosé, Sílvia de , Benavente, Yolanda , Cocco, Pierluigi , Staines, Anthony , Foretová, Lenka , Brennan, Paul , Lan, Qing , Zheng, Tongzhang, Purdue, Mark P. , Armstrong, Bruce K. , Kricker, Anne , Vajdic, Claire M. , Grulich, Andrew E. , Smith, Martyn T. , Bracci, Paige M. , Hartge, Patricia, Cerhan, James R. , Wang, Sophia , Rothman, Nathaniel , Skibola, Christine F., Slager, Susan L. , Brooks‐Wilson, Angela , Shanafelt, Tait D. , Cozen, Wendy , Maynadié, Marc , Boffetta, Paolo , Zhang, Yawei , Chanock, Stephen Jacob , Cerhan, James R , Cocco, Pierluigi , Vajdic, Claire M , Morton, Lindsay M , De Roos, Anneclaire J , Wang, Sophia S

Mayo Clinic

Blood | October 10, 2012 | Volume: 120 | Issue: 23 | Pages: 4645-4648

10.1182/blood-2012-05-427989 | PMID 23047821 Get It

AbstractMany common genetic variants have been associated with non-Hodgkin lymphoma (NHL), but individual study results are often conflicting. To confirm the role of putative risk alleles in B-cell NHL etiology, we performed a validation genotyping study of 67 candidate single nucleotide polymorphisms within InterLymph, a large international consortium of NHL case-control studies. A meta-analysis was performed on data from 5633 B-cell NHL cases and 7034 controls from 8 InterLymph studies. rs3789068 in the proapoptotic BCL2L11 gene was associated with an increased risk for B-cell NHL (odds ratio = 1.21, P random = 2.21 × 10−11), with similar risk estimates for common B-cell subtypes. PRRC2A rs3132453 in the HLA complex class III region conferred a reduced risk of B-cell NHL (odds ratio = 0.68, P random = 1.07 × 10−9) and was likewise evident for common B-cell subtypes. These results are consistent with the known biology of NHL and provide insights into shared pathogenic components, including apoptosis and immune regulation, for the major B-cell lymphoma subtypes.